Maenaka K - Search Results

1

Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas.

Chiba M, Shimono J, Ishio T, Takei N, Kasahara K, Ogasawara R, Ara T, Goto H, Izumiyama K, Otsuguro S, Perera LP, Hasegawa H, Maeda M, Hashino S, Maenaka K, Teshima T, Waldmann TA, Yang Y, Nakagawa M. Chiba M, et al. Among authors: maenaka k. Blood. 2022 Nov 3;140(18):1951-1963. doi: 10.1182/blood.2022015646. Blood. 2022. PMID: 35921533 Free PMC article.

2

Osteopontin-integrin interaction as a novel molecular target for antibody-mediated immunotherapy in adult T-cell leukemia.

Maeda N, Ohashi T, Chagan-Yasutan H, Hattori T, Takahashi Y, Harigae H, Hasegawa H, Yamada Y, Fujii M, Maenaka K, Uede T. Maeda N, et al. Among authors: maenaka k. Retrovirology. 2015 Nov 24;12:99. doi: 10.1186/s12977-015-0225-x. Retrovirology. 2015. PMID: 26597716 Free PMC article.

3

Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells.

Tsukamoto Y, Ohtsu N, Echizenya S, Otsuguro S, Ogura R, Natsumeda M, Isogawa M, Aoki H, Ichikawa S, Sakaitani M, Matsuda A, Maenaka K, Fujii Y, Kondo T. Tsukamoto Y, et al. Among authors: maenaka k. Stem Cells. 2016 Aug;34(8):2016-25. doi: 10.1002/stem.2380. Epub 2016 May 17. Stem Cells. 2016. PMID: 27090194

4

Divergent synthesis of kinase inhibitor derivatives, leading to discovery of selective Gck inhibitors.

Matsumaru T, Inai M, Ishigami K, Iwamatsu T, Maita H, Otsuguro S, Nomura T, Matsuda A, Ichikawa S, Sakaitani M, Shuto S, Maenaka K, Kan T. Matsumaru T, et al. Among authors: maenaka k. Bioorg Med Chem Lett. 2017 May 15;27(10):2144-2147. doi: 10.1016/j.bmcl.2017.03.055. Epub 2017 Mar 23. Bioorg Med Chem Lett. 2017. PMID: 28385506 Free article.

5

Ribavirin-related compounds exert in vitro inhibitory effects toward rabies virus.

Anindita PD, Sasaki M, Okada K, Ito N, Sugiyama M, Saito-Tarashima N, Minakawa N, Shuto S, Otsuguro S, Ichikawa S, Matsuda A, Maenaka K, Orba Y, Sawa H. Anindita PD, et al. Among authors: maenaka k. Antiviral Res. 2018 Jun;154:1-9. doi: 10.1016/j.antiviral.2018.03.011. Epub 2018 Mar 28. Antiviral Res. 2018. PMID: 29601893 Free article.

6

Suramin, screened from an approved drug library, inhibits HuR functions and attenuates malignant phenotype of oral cancer cells.

Kakuguchi W, Nomura T, Kitamura T, Otsuguro S, Matsushita K, Sakaitani M, Maenaka K, Tei K. Kakuguchi W, et al. Among authors: maenaka k. Cancer Med. 2018 Dec;7(12):6269-6280. doi: 10.1002/cam4.1877. Epub 2018 Nov 18. Cancer Med. 2018. PMID: 30449075 Free PMC article.

7

Repurposing existing drugs: identification of irreversible IMPDH inhibitors by high-throughput screening.

Sarwono AEY, Mitsuhashi S, Kabir MHB, Shigetomi K, Okada T, Ohsaka F, Otsuguro S, Maenaka K, Igarashi M, Kato K, Ubukata M. Sarwono AEY, et al. Among authors: maenaka k. J Enzyme Inhib Med Chem. 2019 Dec;34(1):171-178. doi: 10.1080/14756366.2018.1540474. J Enzyme Inhib Med Chem. 2019. PMID: 30451014 Free PMC article.

8

Novel Notch signaling inhibitor NSI‑1 suppresses nuclear translocation of the Notch intracellular domain.

Shiraishi T, Sakaitani M, Otsuguro S, Maenaka K, Suzuki T, Nakaya T. Shiraishi T, et al. Among authors: maenaka k. Int J Mol Med. 2019 Oct;44(4):1574-1584. doi: 10.3892/ijmm.2019.4280. Epub 2019 Jul 19. Int J Mol Med. 2019. PMID: 31364722

9

Antitumor Effect of Sugar-Modified Cytosine Nucleosides on Growth of Adult T-Cell Leukemia Cells in Mice.

Maeda N, Matsuda A, Otsuguro S, Takahashi M, Fujii M, Maenaka K. Maeda N, et al. Among authors: maenaka k. Vaccines (Basel). 2020 Nov 5;8(4):658. doi: 10.3390/vaccines8040658. Vaccines (Basel). 2020. PMID: 33167425 Free PMC article.

10

Application of Acoustic Ejection MS System to High-Throughput Screening for SARS-CoV-2 3CL Protease Inhibitors.

Hasegawa T, Imamura RM, Suzuki T, Hashiguchi T, Nomura T, Otsuguro S, Maenaka K, Sasaki M, Orba Y, Sawa H, Sato A, Okabe T, Nagano T, Kojima H. Hasegawa T, et al. Among authors: maenaka k. Chem Pharm Bull (Tokyo). 2022 Mar 1;70(3):199-201. doi: 10.1248/cpb.c21-01003. Epub 2021 Dec 21. Chem Pharm Bull (Tokyo). 2022. PMID: 34937844 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

220 results

Search Page